NHS England to offer targeted SABR radiotherapy for early prostate cancer, reducing treatment sessions from 20 to 5
By
Jane Kirby
Toasted golden, schmeared with insight. Top of the rack.
Summary
NHS England will offer stereotactic radiotherapy (SABR) to thousands of men with early prostate cancer across all 48 radiotherapy centres within three months. This highly targeted treatment reduces required sessions from over 20 to just five, delivering higher radiation doses from different angles to spare healthy tissue, reduce side effects, and cut the risk of tumour growth or spread. Prostate cancer is the most common cancer in men in the UK, with over 55,000 diagnoses annually.
Key quotes
· 4 pulledThousands of men with prostate cancer in England will be offered a new, highly targeted radiotherapy on the NHS, slashing their required doses from over 20 to just five.
Stereotactic radiotherapy (SABR) is an effective, focused treatment that delivers higher radiation doses in fewer sessions, reducing side effects and cutting the risk of tumour growth or spread.
Beams are directed from different angles, sparing healthy tissue.
NHS England has announced that all 48 radiotherapy centres across the country will begin offering SABR to men with early prostate cancer within the next three months.
You might also wanna read
CERN and Theryq Collaborate on FLASH Radiotherapy for Cancer Treatment
French company Theryq is collaborating with CERN to develop FLASH radiotherapy, a new cancer treatment approach using ultra-high dose rate r
spectrum.ieee.org·3mo ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·10d ago
Australian melanoma pioneer Richard Scolyer dies after experimental brain tumour treatment
Dr. Richard Scolyer, a pioneering Australian melanoma researcher, has died at age 59 from glioblastoma, three years after his diagnosis. He
bbc.com·2d ago
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·10mo ago